Short answer
Anika Therapeutics, Inc. (ANIK) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $33M (up 15.6% year over year) with net income of $3M.
Q2 2026 key financials · XBRL
- Revenue
- $33M
- +15.6% YoY · +10.1% QoQ
- Net income
- $3M
- +183.4% YoY · +165.4% QoQ
- Operating margin
- 9.1%
- Gross margin
- 65.1%
- EPS (diluted)
- $0.24
- +185.7% YoY · +164.9% QoQ
Source: XBRL data from the Anika Therapeutics, Inc. (ANIK) Q2 2026 10-Q on SEC EDGAR. USD.
Anika Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $32.6M, up $4.4M or 16% YoY
- Gross margin 65% vs 51% YoY, driven by volume, production, and sales mix
- OEM channel $18.7M, up 14%; Commercial channel $13.9M, up 17%
- Cash $38.4M vs $57.5M at December 31, 2025; operating cash flow used $5.5M
- Cingal NDA timing remains subject to CMC and regulatory requirements; Hyalofast PMA review ongoing after January 2026 deficiency letter
Risk Factors
- Risk Factors section not provided; filing excerpt covers Items 2–6 only
- No basis to identify newly added or materially updated risks versus the 10-K
- No regulatory, legal, compliance, operational, competitive, market, or financial risk factors disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anika Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.